Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Total Therapy III (TT3) for Multiple Myeloma
NCT00081939Phase 2Completed
- Sponsor
- University of Arkansas
- Start
- Jan 2004
- Primary completion
- Sep 2014
- Modality
- Small Molecules, Modified Peptides
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bortezomib in multiple myeloma (MM), sponsored by University of Arkansas. Primary endpoint: Progression-Free Survival at 3 years. Started Jan 2004; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT00081939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00081939.